Government
San Francisco City Leaders To Consider Psychedelics Decriminalization Measure
The San Francisco Board of Supervisors will consider a proposal to decriminalize natural psychedelic drugs including psilocybin mushrooms and ayahuasca.
City leaders in San Francisco will consider a proposed ordinance to decriminalize the use of natural psychedelics including psilocybin and ayahuasca when the Board of Supervisors returns from recess next month. The measure, which was introduced by San Francisco Supervisors Dean Preston and Hillary Ronen on July 26, would also encourage the state of California to reform its psychedelic drugs policy.
If adopted by the Board of Supervisors, the ordinance would call on the San Francisco Police Department to make enforcement of laws banning the possession, use, cultivation and transfer of entheogenic plants and fungi including psilocybin mushrooms and ayahuasca and their active components by adults “amongst the lowest priority for the City and County of San Francisco,” according to the text of the proposal.
The ordinance also requests that city resources not be used for “any investigation, detention, arrest, or prosecution arising out of alleged violations of state and federal law regarding the use of Entheogenic Plants listed on the Federally Controlled Substances Schedule 1 list.”
Preston has been critical of the SFPD’s recent increase in enforcement of laws criminalizing drug use. But he noted that decriminalizing natural psychedelics is a different matter.
“We’re not talking about addictive substances here. Around this particular category, I would hope that even folks who disagree around the best approaches to dealing with opioids and other drugs prevalent in San Francisco would agree with deprioritizing enforcement around entheogenic plants,” Preston said, adding that research has shown psychedelics have the potential to treat several serious mental health issues including substance abuse.
The Evolution of Psychedelics Policy
Preston noted that the measure would bring San Francisco policy in line with the movement to look at psychedelics in a new light after decades of stigma and criminalization.
“The law hasn’t evolved at all since then, and these substances are treated the way they always have been,” Preston said. “At the same time, the scientific community has been expanding their study and research into their therapeutic use.”
Michael Pollan, a co-founder of the Berkeley Center for the Science of Psychedelics and the creator of a recent Netflix documentary series on the drugs, said that entheogenic plants can be used therapeutically, but warned they should be used with caution.
“These substances have enormous potential, but they are not for everyone and they carry serious risks when used improperly,” Pollan said at a recent news conference. “The shift from destroyer of young minds in the ’60s to effective medicine in the 2020s is as sudden as it is confusing to many people. So we want to address that confusion and that curiosity with solid, credible information from a trusted source.”
“Not many people were doing basic science, trying to understand how it is that psychedelics have the effects they have and why they’re effective in the treatment of various mental disorders,” Pollan added. “We want to figure out what psychedelics might teach us about things like perception, predictive processing, belief change and brain plasticity.”
If the psychedelics decriminalization ordinance is approved by the San Francisco Board of Supervisors, the city would become the largest municipality to enact such a measure. Denver was the first city in the nation to decriminalize psychedelics in 2019, and since that time others including Oakland and Santa Cruz, California, Ann Arbor, Michigan and Easthampton, Massachusetts have adopted similar ordinances. And two years ago, voters in Oregon approved groundbreaking legislation to legalize psilocybin for therapeutic use.
“One of the striking things about the Oregon experiment, which passed by ballot initiative in 2020, is that it will make a guided psychedelic experience available to anyone over 21, regardless of diagnosis,” said Pollan. “I do think that the use of psychedelics will not be restricted to the medical system. It’s not now and won’t be in the future.”
Dr. Markus Roggen, the president and chief science officer of psychedelics and cannabis research and development firm Delic Labs, said he supports the intent of the San Francisco psychedelics proposal.
“I welcome decriminalization from a philosophical point, as criminalizing ‘drug’ possession/use has brought many costs and pains to the country,” Roggen wrote in an email to High Times.
But he added that he does not believe decriminalization goes far enough and that past harms caused by the criminalization of psychedelic drugs need to be righted. He also said that decriminalization should include regulation, noting the thriving illicit psychedelics industry in the Netherlands.
“There the use is legal but production illegal,” said Roggen. “The government handed this whole industry to the cartels and mafia.”
The San Francisco Board of Supervisors will take up the psychedelics decriminalization measure when it returns from recess in September.
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
Marijuana companies suing US attorney general in federal prohibition challenge
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business11 months agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business11 months agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business11 months agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business1 year agoCan Cannabis Help Seasonal Depression
-
Blogs1 year agoCannabis Art Is Flourishing On Etsy